Genetically mediated DCM, HCM, and ACM each have their own considerations for optimal disease modeling, including culture conditions, loading conditions, cellular sources, cellular make up, proper controls, and the outputs that are properly reflective of human disease. Consensus is evolving for the best approaches to model each cardiomyopathy and will be explored in this session.
Assessing therapeutics in model systems:
Current regulatory guidelines call for functional outputs and higher throughput assays as being essential components of NAM methodologies, however gold standards in cardiovascular disease modeling are still being debated and will be discussed in this session.
The evolving regulatory landscape:
While regulators are beginning to embrace NAMs, the guidance on the use of NAMs in cardiovascular disease is still evolving. Consideration of the cardiomyopathy type, the known biology, the gene involved, and relevant functional outputs are likely to require comprehensive individualized assessments for regulatory considerations.In the last 20 years, tremendous basic science and clinical research have accelerated the field of precision cardiovascular medicine and laid the foundation for ongoing clinical trials. When coupled with FDA guidance to incorporate NAMs in preclinical testing, precision cardiovascular medicine will likely undergo a rapid evolution as the promise of CRISPR-based therapies and genotype specific therapeutic strategies advance. Critically, strategic collaboration among researchers, regulators, and clinicians will be essential to translate these advances into tangible benefits for patients.
HT
Dr. Hanna Tadros
Pediatric Cardiology · Pediatric Heart Failure & TransplantationBaylor College of Medicinehanna